Advertisement

Genetic Implications of Ocular Melanoma

  • Mona Mohammad
  • Mandeep S. SagooEmail author
Chapter
Part of the Current Practices in Ophthalmology book series (CUPROP)

Abstract

Uveal melanoma treatment has good local control but still half the patients develop metastatic disease and the systemic prognosis when metastasis develops is still poor. Hence there is a need to identify high-risk features for early detection and targeted therapeutic treatment. The cytogenetics of uveal melanoma has come a long way with still unanswered questions.

Keywords

Uveal melanoma Cytogenetics Prognostication 

References

  1. 1.
    Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118(9):1881–5.PubMedGoogle Scholar
  2. 2.
    Virgili G, et al. Survival in patients with uveal melanoma in Europe. Arch Ophthalmol. 2008;126(10):1413–8.PubMedGoogle Scholar
  3. 3.
    Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol. 2006;124(12):1684–93.Google Scholar
  4. 4.
    Vasalaki M, et al. Ocular oncology: advances in retinoblastoma, uveal melanoma and conjunctival melanoma. Br Med Bull. 2017;121(1):107–19.PubMedGoogle Scholar
  5. 5.
    Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol. 2001;119(5):670–6.Google Scholar
  6. 6.
    Diener-West M, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group report no. 26. Arch Ophthalmol. 2005;123(12):1639–43.Google Scholar
  7. 7.
    McLean IW, Foster WD, Zimmerman LE. Uveal melanoma: location, size, cell type, and enucleation as risk factors in metastasis. Hum Pathol. 1982;13(2):123–32.PubMedGoogle Scholar
  8. 8.
    Al-Jamal RT, Makitie T, Kivela T. Nucleolar diameter and microvascular factors as independent predictors of mortality from malignant melanoma of the choroid and ciliary body. Invest Ophthalmol Vis Sci. 2003;44(6):2381–9.PubMedGoogle Scholar
  9. 9.
    White VA, et al. Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma. Cancer. 1998;83(2):354–9.PubMedGoogle Scholar
  10. 10.
    Sisley K, et al. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer. 1997;19(1):22–8.PubMedGoogle Scholar
  11. 11.
    Scholes AG, et al. Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival. Invest Ophthalmol Vis Sci. 2003;44(3):1008–11.PubMedGoogle Scholar
  12. 12.
    Kaliki S, Shields CL, Shields JA. Uveal melanoma: estimating prognosis. Indian J Ophthalmol. 2015;63(2):93–102.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Augsburger JJ, Correa ZM, Trichopoulos N. Prognostic implications of cytopathologic classification of melanocytic uveal tumors evaluated by fine-needle aspiration biopsy. Arq Bras Oftalmol. 2013;76(2):72–9.PubMedGoogle Scholar
  14. 14.
    Chang MY, McCannel TA. Comparison of uveal melanoma cytopathologic sample retrieval in trans-scleral versus vitrectomy-assisted transvitreal fine needle aspiration biopsy. Br J Ophthalmol. 2014;98(12):1654–8.PubMedGoogle Scholar
  15. 15.
    Schopper VJ, Correa ZM. Clinical application of genetic testing for posterior uveal melanoma. Int J Retina Vitreous. 2016;2:4.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Prescher G, Bornfeld N, Becher R. Nonrandom chromosomal abnormalities in primary uveal melanoma. J Natl Cancer Inst. 1990;82(22):1765–9.PubMedGoogle Scholar
  17. 17.
    Patel KA, et al. Prediction of prognosis in patients with uveal melanoma using fluorescence in situ hybridisation. Br J Ophthalmol. 2001;85(12):1440–4.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Shields CL, et al. Personalized prognosis of uveal melanoma based on cytogenetic profile in 1059 patients over an 8-year period: the 2017 Harry S. Gradle lecture. Ophthalmology. 2017;124(10):1523–31.PubMedGoogle Scholar
  19. 19.
    Tschentscher F, et al. Partial deletions of the long and short arm of chromosome 3 point to two tumor suppressor genes in uveal melanoma. Cancer Res. 2001;61(8):3439–42.PubMedGoogle Scholar
  20. 20.
    White VA, McNeil BK, Horsman DE. Acquired homozygosity (isodisomy) of chromosome 3 in uveal melanoma. Cancer Genet Cytogenet. 1998;102(1):40–5.PubMedGoogle Scholar
  21. 21.
    Aalto Y, et al. Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42(2):313–7.PubMedGoogle Scholar
  22. 22.
    Damato B, et al. Multiplex ligation-dependent probe amplification of uveal melanoma: correlation with metastatic death. Invest Ophthalmol Vis Sci. 2009;50(7):3048–55.PubMedGoogle Scholar
  23. 23.
    Kilic E, et al. Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-free survival in uveal melanoma patients. Invest Ophthalmol Vis Sci. 2005;46(7):2253–7.PubMedGoogle Scholar
  24. 24.
    Tschentscher F, et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res. 2003;63(10):2578–84.PubMedGoogle Scholar
  25. 25.
    Onken MD, et al. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004;64(20):7205–9.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Onken MD, et al. Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. Cancer Res. 2006;66(9):4602–9.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Chang SH, et al. Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis. Melanoma Res. 2008;18(3):191–200.PubMedGoogle Scholar
  28. 28.
    Kivela T, Kujala E. Prognostication in eye cancer: the latest tumor, node, metastasis classification and beyond. Eye (Lond). 2013;27(2):243–52.Google Scholar
  29. 29.
    Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Walter SD, et al. Prognostic implications of tumor diameter in association with gene expression profile for uveal melanoma. JAMA Ophthalmol. 2016;134(7):734–40.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Damato B, et al. Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology. 2007;114(10):1925–31.PubMedGoogle Scholar
  32. 32.
    Augsburger JJ, Correa ZM, Augsburger BD. Frequency and implications of discordant gene expression profile class in posterior uveal melanomas sampled by fine needle aspiration biopsy. Am J Ophthalmol. 2015;159(2):248–56.PubMedGoogle Scholar
  33. 33.
    Field MG, Harbour JW. Recent developments in prognostic and predictive testing in uveal melanoma. Curr Opin Ophthalmol. 2014;25(3):234–9.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Saldanha G, et al. High BRAF mutation frequency does not characterize all melanocytic tumor types. Int J Cancer. 2004;111(5):705–10.PubMedGoogle Scholar
  35. 35.
    Zuidervaart W, et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer. 2005;92(11):2032–8.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Fecher LA, et al. Toward a molecular classification of melanoma. J Clin Oncol. 2007;25(12):1606–20.PubMedGoogle Scholar
  37. 37.
    van den Bosch T, et al. Genetics of uveal melanoma and cutaneous melanoma: two of a kind? Dermatol Res Pract. 2010;2010:360136.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Davies H, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.PubMedGoogle Scholar
  39. 39.
    Pollock PM, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33(1):19–20.PubMedGoogle Scholar
  40. 40.
    Onken MD, et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci. 2008;49(12):5230–4.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Van Raamsdonk CD, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457(7229):599–602.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Van Raamsdonk CD, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363(23):2191–9.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Wan PT, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855–67.PubMedGoogle Scholar
  44. 44.
    Bauer J, et al. Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. Br J Cancer. 2009;101(5):813–5.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Harbour JW, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330(6009):1410–3.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Jensen DE, et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene. 1998;16(9):1097–112.PubMedGoogle Scholar
  47. 47.
    Dey A, et al. Loss of the tumor suppressor BAP1 causes myeloid transformation. Science. 2012;337(6101):1541–6.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Gupta MP, et al. Clinical characteristics of uveal melanoma in patients with germline BAP1 mutations. JAMA Ophthalmol. 2015;133(8):881–7.PubMedGoogle Scholar
  49. 49.
    Rai K, et al. Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet. 2016;89(3):285–94.PubMedGoogle Scholar
  50. 50.
    Rednam KR, et al. Uveal melanoma in association with multiple malignancies. A case report and review. Retina. 1981;1(2):100–6.PubMedGoogle Scholar
  51. 51.
    Masoomian B, Shields JA, Shields CL. Overview of BAP1 cancer predisposition syndrome and the relationship to uveal melanoma. J Curr Ophthalmol. 2018;30(2):102–9.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Helgadottir H, Hoiom V. The genetics of uveal melanoma: current insights. Appl Clin Genet. 2016;9:147–55.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Papaemmanuil E, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365(15):1384–95.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Wang L, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365(26):2497–506.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Yavuzyigitoglu S, et al. Uveal melanomas with SF3B1 mutations: a distinct subclass associated with late-onset metastases. Ophthalmology. 2016;123(5):1118–28.PubMedGoogle Scholar
  56. 56.
    Martin M, et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet. 2013;45(8):933–6.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Decatur CL, et al. Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes. JAMA Ophthalmol. 2016;134(7):728–33.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Augsburger JJ, Correa ZM, Shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol. 2009;148(1):119–27.PubMedGoogle Scholar
  59. 59.
    Patel M, et al. Therapeutic implications of the emerging molecular biology of uveal melanoma. Clin Cancer Res. 2011;17(8):2087–100.PubMedGoogle Scholar
  60. 60.
    Sagoo MS, et al. Combined PKC and MEK inhibition for treating metastatic uveal melanoma. Oncogene. 2014;33(39):4722–3.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Amirouchene-Angelozzi N, et al. Upcoming translational challenges for uveal melanoma. Br J Cancer. 2015;113(12):1746.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Ambrosini G, et al. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance. Clin Cancer Res. 2012;18(13):3552–61.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Selumetinib shows promise in metastatic uveal melanoma. Cancer Discov. 2013;3(7):OF8.Google Scholar
  64. 64.
    Carvajal RD. et al. Pharmacodynamic activity of selumetinib to predict radiographic response in advanced uveal melanoma. American Society of Clinical Oncology; 2012.Google Scholar
  65. 65.
    Carvajal RD, et al. Effect of selumetinib vs. chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014;311(23):2397–405.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Ocular Oncology ServiceMoorfields Eye HospitalLondonUK
  2. 2.NIHR Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital and UCL Institute of OphthalmologyLondonUK

Personalised recommendations